Table 2.
Baseline characteristics of patients with new-onset and relapse of nephrotic syndrome after receiving COVID-19 vaccination
| Characteristic | All cases (n = 27) | New-onset (n = 6) | Relapse (n = 21) |
|---|---|---|---|
| Age (years) | |||
| ≤ 19 | 3 | 0 | 3 |
| 20–29 | 4 | 0 | 4 |
| 30–39 | 3 | 0 | 3 |
| 40–49 | 2 | 1 | 1 |
| 50–59 | 2 | 0 | 2 |
| 60–69 | 6 | 1 | 5 |
| ≥ 70 | 7 | 4 | 3 |
| Sex | |||
| Female | 12 | 2 | 10 |
| Male | 15 | 4 | 11 |
| Treatments before this event (multiple answers allowed) | |||
| No treatment | 10 | 6 | 4 |
| Oral corticosteroid | 15 | 0 | 15 |
| Steroid pulse therapy | 3 | 0 | 3 |
| Immunosuppressive therapy (except for rituximab) | 10 | 0 | 10 |
| Rituximab | 3 | 0 | 3 |
| RAS-I | 7 | 0 | 7 |
| Antiplatelet drugs | 1 | 0 | 1 |
| Type of the vaccine | |||
| COMIRNATY Intramuscular Injection (Pfizer-BioNTech) | 23 | 5 | 18 |
| COVID-19 Vaccine Moderna Intramuscular Injection (Moderna/Takeda) | 1 | 0 | 1 |
| Unknown | 3 | 1 | 2 |
| Vaccination dose | |||
| First dose | 8 | 1 | 7 |
| Second dose | 18 | 4 | 14 |
| Both first and second doses | 1 | 1 | 1 |
| Histopathological diagnoses revealed by the kidney biopsy | |||
| Minimal change disease | 12 | 2 | 10 |
| Focal segmental glomerulosclerosis | 2 | 0 | 2 |
| Membranous nephropathy | 4 | 2 | 2 |
| IgA nephropathy | 2 | 1 | 1 |
| Membranoproliferative glomerulonephritis | 1 | 0 | 1 |
| C3 glomerulopathy | 2 | 0 | 2 |
| Unknown/did not answer | 4 | 1 | 3 |
| Adverse reactions (multiple answers allowed) | |||
| Fever (≥ 37.5 ℃) | 5 | 0 | 5 |
| Fatigue | 8 | 0 | 8 |
| Headache | 1 | 0 | 1 |
| Chills | 0 | 0 | 0 |
| Muscle pain | 6 | 2 | 4 |
| Pain at the application site | 1 | 0 | 1 |
| Joint pain | 2 | 0 | 2 |
| None | 2 | 0 | 2 |
| Unknown | 8 | 4 | 4 |
COVID-19 coronavirus disease 2019, RAS-I renin–angiotensin system inhibitor